Bruton Tyrosine Kinase (BTK) Inhibitors (VA-24-00023127)   3

Pre-solicitation Notice The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79724R0007 for an unrestricted procurement for Bruton Tyrosine Kinase (BTK) Inhibitors for the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC or UPC number that is unique to the offeror. Solicitation # 36E79724R0007 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about February 8, 2024, with a tentative closing date of February 22, 2024. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: https://sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Ray Roldan. Questions can be e-mailed to: Raymond.roldan@va.gov. The estimated annual requirements are as follows: Item Description Units (Tablets or Capsules) per Day Total For New Patients 1A Ibrutinib Capsules 140MG 3 2,444 OR OR OR OR 1B Acalabrutinib Tablets 100MG 2 2,444 OR OR OR OR 1C Zanubrutinib Capsules 80MG 4 2,444 The price evaluation will be completed by multiplying the proposed BTK Inhibitors price by the number of units per day required per patient to calculate a cost per day. This cost per day will then be multiplied by the estimated number of patients (a total of 2,444 for all participating agencies) for the proposed product and 365 (days per year) to calculate a total cost per year. The required number of units per patient per day are listed in the table above for each item (1A, 1B, 1C). The offeror must make all package sizes for the eligible strengths available. All proposed/awarded package sizes will be awarded at the same price per capsule/tablet. The awarded product will be the only agent listed on the VA National Formulary for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) indications and will required be for new patient starts. Patients already taking one of the versions not awarded are not mandated to be switched over to the awarded version and are not included in the annual estimates above. However, patients currently taking a version that is not awarded may be switched over to the awarded version for clinical reasons.